The Warburg effect and its cancer therapeutic implications

被引:287
作者
Chen, Zhao [1 ]
Lu, Weiqin [1 ]
Garcia-Prieto, Celia [1 ]
Huang, Peng [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA
关键词
Warburg effect; glycolysis; inhibitor; mitochondria; cancer therapeutics; drug resistance; reactive oxygen species (ROS); oncogene; hypoxia;
D O I
10.1007/s10863-007-9086-x
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Increased aerobic glycolysis in cancer, a phenomenon known as the Warburg effect, has been observed in various tumor cells and represents a major biochemical alteration associated with malignant transformation. Although the exact molecular mechanisms underlying this metabolic change remain to be elucidated, the profound biochemical alteration in cancer cell energy metabolism provides exciting opportunities for the development of therapeutic strategies to preferentially kill cancer cells by targeting the glycolytic pathway. Several small molecules capable of inhibiting glycolysis in experimental systems have been shown to have promising anticancer activity in vitro and in vivo. This review article provides a brief summary of our current understanding of the Warburg effect, the underlying mechanisms, and its influence on the development of therapeutic strategies for cancer treatment.
引用
收藏
页码:267 / 274
页数:8
相关论文
共 66 条
  • [1] Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631
  • [2] Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes
    Altenberg, B
    Greulich, KO
    [J]. GENOMICS, 2004, 84 (06) : 1014 - 1020
  • [3] ARORA KK, 1988, J BIOL CHEM, V263, P17422
  • [4] BARNARD JP, 1993, J BIOL CHEM, V268, P3654
  • [5] TIGAR, a p53-inducible regulator of glycolysis and apoptosis
    Bensaad, Karim
    Tsuruta, Atsushi
    Selak, Mary A.
    Calvo Vidal, M. Nieves
    Nakano, Katsunori
    Bartrons, Ramon
    Gottlieb, Eyal
    Vousden, Karen H.
    [J]. CELL, 2006, 126 (01) : 107 - 120
  • [6] Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: Final results of a phase III study with a factorial design
    Berruti, A
    Bitossi, R
    Gorzegno, G
    Bottini, A
    Alquati, P
    De Matteis, A
    Nuzzo, F
    Giardina, G
    Danese, S
    De Lena, M
    Lorusso, V
    Farris, A
    Sarobba, MG
    DeFabiani, E
    Bonazzi, G
    Castiglione, F
    Bumma, C
    Moro, G
    Bruzzi, P
    Dogliotti, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) : 4150 - 4159
  • [7] Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis
    Biaglow, JE
    Cerniglia, G
    Tuttle, S
    Bakanauskas, V
    Stevens, C
    McKenna, G
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 235 (03) : 739 - 742
  • [8] Aerobic glycolysis by proliferating cells: A protective strategy against reactive oxygen species
    Brand, KA
    Hermfisse, U
    [J]. FASEB JOURNAL, 1997, 11 (05) : 388 - 395
  • [9] Mitochondrial mutations in cancer
    Brandon, M.
    Baldi, P.
    Wallace, D. C.
    [J]. ONCOGENE, 2006, 25 (34) : 4647 - 4662
  • [10] Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer.: A phase II trial of the EORTC-new drug development group
    Briasoulis, E
    Pavlidis, N
    Terret, C
    Bauer, J
    Fiedler, W
    Schöffski, P
    Raoul, JL
    Hess, D
    Selvais, R
    Lacombe, D
    Bachmann, P
    Fumoleau, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (16) : 2334 - 2340